Core Points - NKGen Biotech has received Fast Track designation from the FDA for its investigational therapy troculeucel, aimed at treating moderate Alzheimer's disease [2][3] - The Fast Track designation is designed to expedite the development and review process for therapies addressing serious health conditions and unmet medical needs [4] - NKGen is currently enrolling patients in a Phase 2a trial for troculeucel and anticipates sharing updated clinical data by the end of 2025 [3] Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous and allogeneic natural killer (NK) cell therapeutics [6] - The company is headquartered in Santa Ana, California, and is dedicated to addressing serious medical conditions through its innovative therapies [6] Product Information - Troculeucel is an ex vivo expanded autologous NK cell therapy being developed for neurodegenerative disorders and various cancers [5] - The International Nonproprietary Name (INN) for troculeucel is SNK01, which has been approved by the World Health Organization [5]
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease